Jeffers M, Xi C, Bapuji R, Wotherspoon H, Kimmelman J, Bedford P
BMC Med. 2024; 22(1):487.
PMID: 39443960
PMC: 11515533.
DOI: 10.1186/s12916-024-03690-8.
Rivetti di Val Cervo P, Alessi E, Lastella M, La Greca A, Trotta F
BioDrugs. 2024; 38(6):831-844.
PMID: 39404995
PMC: 11530470.
DOI: 10.1007/s40259-024-00683-0.
Fachel F, Schuh R, Grudzinski P, Teixeira H, Baldo G, Matte U
Ther Innov Regul Sci. 2023; 58(1):21-33.
PMID: 37815738
DOI: 10.1007/s43441-023-00578-2.
Salmikangas P, Carlsson B, Klumb C, Reimer T, Thirstrup S
Front Med (Lausanne). 2023; 10:1190016.
PMID: 37215709
PMC: 10196484.
DOI: 10.3389/fmed.2023.1190016.
Landfeldt E
J Neuromuscul Dis. 2022; 9(6):675-688.
PMID: 36314216
PMC: 9697054.
DOI: 10.3233/JND-221540.
GMP Compliant Production of a Cryopreserved Adipose-Derived Stromal Cell Product for Feasible and Allogeneic Clinical Use.
Haack-Sorensen M, Monsted Johansen E, Hojgaard L, Kastrup J, Ekblond A
Stem Cells Int. 2022; 2022:4664917.
PMID: 35769340
PMC: 9236818.
DOI: 10.1155/2022/4664917.
Current landscape of clinical development and approval of advanced therapies.
Iglesias-Lopez C, Agusti A, Vallano A, Obach M
Mol Ther Methods Clin Dev. 2021; 23:606-618.
PMID: 34901306
PMC: 8626628.
DOI: 10.1016/j.omtm.2021.11.003.
The Essential Need for a Validated Potency Assay for Cell-Based Therapies in Cardiac Regenerative and Reparative Medicine. A Practical Approach to Test Development.
Gomez-Cid L, Grigorian-Shamagian L, Sanz-Ruiz R, S de la Nava A, Fernandez A, Fernandez-Santos M
Stem Cell Rev Rep. 2021; 17(6):2235-2244.
PMID: 34463902
PMC: 8599250.
DOI: 10.1007/s12015-021-10244-5.
Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs.
Drago D, Foss-Campbell B, Wonnacott K, Barrett D, Ndu A
Mol Ther Methods Clin Dev. 2021; 21:524-529.
PMID: 33997101
PMC: 8099595.
DOI: 10.1016/j.omtm.2021.04.001.
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.
Heidbuechel J, Engeland C
J Hematol Oncol. 2021; 14(1):63.
PMID: 33863363
PMC: 8052795.
DOI: 10.1186/s13045-021-01075-5.
Towards a better use of scientific advice for developers of advanced therapies.
Tavridou A, Rogers D, Bonelli M, Schiel A, Hidalgo-Simon A
Br J Clin Pharmacol. 2020; 87(6):2459-2464.
PMID: 33237580
PMC: 8247399.
DOI: 10.1111/bcp.14672.
Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals.
Elsallab M, Bravery C, Kurtz A, Abou-El-Enein M
Mol Ther Methods Clin Dev. 2020; 18:269-279.
PMID: 32637456
PMC: 7327881.
DOI: 10.1016/j.omtm.2020.05.035.
Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee.
Flynn R, Hedenmalm K, Murray-Thomas T, Pacurariu A, Arlett P, Shepherd H
Clin Pharmacol Ther. 2020; 107(4):957-965.
PMID: 31955404
PMC: 7158204.
DOI: 10.1002/cpt.1775.
generated human CAR T cells eradicate tumor cells.
Agarwal S, Weidner T, Thalheimer F, Buchholz C
Oncoimmunology. 2019; 8(12):e1671761.
PMID: 31741773
PMC: 6844313.
DOI: 10.1080/2162402X.2019.1671761.
Beyond the Present Constraints That Prevent a Wide Spread of Tissue Engineering and Regenerative Medicine Approaches.
ODonnell B, Ives C, Mohiuddin O, Bunnell B
Front Bioeng Biotechnol. 2019; 7:95.
PMID: 31134194
PMC: 6514054.
DOI: 10.3389/fbioe.2019.00095.
